首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Comparative efficacies of ciprofloxacin amoxicillin amoxicillin-clavulanic acid and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.
【2h】

Comparative efficacies of ciprofloxacin amoxicillin amoxicillin-clavulanic acid and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.

机译:环丙沙星阿莫西林阿莫西林-克拉维酸和头孢克洛对小鼠实验性肺炎链球菌呼吸道感染的比较功效。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Experimental respiratory infections were established in mice by intranasal inoculation of Streptococcus pneumoniae. Inoculation of 10(7) CFU of either S. pneumoniae 1629 or S. pneumoniae 7 produced a fatal pneumonia in nontreated mice 2 to 3 days after infection. Oral therapy was commenced 1 h after infection and was continued three times a day for 2 days. The doses used in mice produced peak concentrations in serum and lung tissue similar to those measured in humans. Ciprofloxacin failed to eliminate either strain of pneumococcus from mouse lungs at any of the doses tested (40, 80, or 160 mg/kg of body weight) by the end of therapy (33 h). Mice that received ciprofloxacin at 160 mg/kg were clear of S. pneumoniae 7 5 days later, whereas persistence and regrowth of S. pneumoniae 1629 resulted in the death of 20% of animals treated with ciprofloxacin. Therapy with cefaclor (20 mg/kg) produced an effect similar to that of ciprofloxacin. In contrast, amoxicillin (10 and 20 mg/kg) and amoxicillin-clavulanic acid (10/5 and 20/10 mg/kg) were significantly (P less than 0.05) more effective in eliminating both strains of S. pneumoniae from the lungs by the end of therapy and, by 168 h, had prevented mortality in 80 to 100% of treated animals. The efficacy of ciprofloxacin against these experimental pneumococcal respiratory infections was poor, despite good penetration into lung tissue, and is a reflection of the low in vitro activity of the quinolone against S. pneumoniae, one of the most common pathogens in community-acquired pneumonia.
机译:通过鼻内接种肺炎链球菌在小鼠中建立了实验性呼吸道感染。感染2至3天后,接种10(7)CFU的肺炎链球菌1629或肺炎链球菌7会导致致命的肺炎。感染后1小时开始口服治疗,每天持续3次,共2天。在小鼠中使用的剂量在血清和肺组织中产生的峰值浓度与在人类中测得的峰值浓度相似。到治疗结束(33小时)时,环丙沙星不能以任何测试剂量(40、80或160 mg / kg体重)从小鼠肺中消除任何一种肺炎球菌。接受环丙沙星剂量为160 mg / kg的小鼠在5天后7天清除了肺炎链球菌,而肺炎链球菌1629的持久性和再生长导致使用环丙沙星治疗的动物死亡20%。头孢克洛(20 mg / kg)治疗产生的作用类似于环丙沙星。相比之下,阿莫西林(10和20 mg / kg)和阿莫西林-克拉维酸(10/5和20/10 mg / kg)在从肺部清除两种肺炎链球菌的效果显着(P小于0.05)。到治疗结束时为止,并且到168小时为止,已经预防了80至100%受治疗动物的死亡。尽管良好地渗透到肺组织中,环丙沙星对这些实验性肺炎球菌呼吸道感染的疗效仍然很差,这反映了喹诺酮抗肺炎链球菌的体外活性低,肺炎链球菌是社区获得性肺炎中最常见的病原体之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号